presentatie - vzw farmaka asbl

Referenties
Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention
For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359:995-1003.
Hannedouche T, Landais P, Goldfarb B et al. Randomised controlled trial of enalapril and beta blockers in nondiabetic
chronic renal failure. BMJ 1994;309:833-7.
Marin R, Ruilope LM, Aljama P et al. A random comparison of fosinopril and nifedipine GITS in patients with
primary renal disease. J Hypertens 2001;19(10):1871-6.
Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A Calcium Antagonist vs a non-calcium Antagonist hypertension
treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril
Study (INVEST): A Randomised Controlled Trial. JAMA 2003;290(21):2805-16.
Progress CG. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals
with previous stroke or transient ischemic attack. Lancet 2001;358:1033-41.
Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies
with non-nephrotic proteinuria. Lancet 1999;354:359-64.
Ruggenenti P, Perna A, Gherardi G et al. Chronic proteinuric nephropathies: outcomes and response to
treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis
2000;35(6):1155-65.
Wright JT Jr, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on
progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-31.
Projekt
Farmaka
Behandeling bij patiënten met gecompliceerde hypertensie
Oktober 2004
˜ Fiche 5 ˜